Women with premature ovarian insufficiency on HT likely to have poor sleep quality
Women who have premature ovarian insufficiency (POI) and are receiving hormone therapy (HT) appear to have poor sleep quality, taking longer to fall asleep and experiencing greater fatigue, according to a recent study.
The cross-sectional study involved 61 women with POI receiving HT (POI group; mean age, 35.03 years) and an identical number of age-matched women with preserved ovarian function (control group; mean age, 34.49 years).
Researchers evaluated sleep quality and fatigue using the Pittsburgh Sleep Quality Index (PSQI) and Chalder Fatigue Scale, respectively. They performed correlation analysis, the Mann-Whitney, chi-square, or Fisher test to compare the said outcomes between the POI and control groups.
Results for the PSQI evaluation showed no significant between-group difference, with mean scores of 7.69 in the POI group and 8.03 in the control group (p=0.79).
However, women in the POI group had higher and therefore worse scores for the sleep latency component (mean, 1.74 and 1.18, respectively; p<0.001) and were more likely to use sleep medications (mean, 1.28 and 0.85; p=0.008). Furthermore, fatigue index was markedly higher than in the control group (mean, 5.25 and 3.49, respectively; p<0.001).
In the POI group, sleep quality was graded as poor in 69 percent of women, while fatigue was present in 59 percent.